The patent play: Bio­gen gets a PhI­II boost for its bit-bet­ter take on the block­buster MS fran­chise drug Tec­fidera

Bio­gen $BI­IB got some mod­est­ly up­beat news from the R&D group to­day on a suc­ces­sor drug to Tec­fidera, their big mul­ti­ple scle­ro­sis fran­chise ther­a­py.

With the help of their col­lab­o­ra­tor Alk­er­mes $ALKS, which spe­cial­izes in me-bet­ter drugs (with mixed re­sults), the part­ners post­ed a fresh set of Phase III da­ta show­ing that their drug Vumer­i­ty — dirox­imel fu­marate — came in with a marked­ly im­proved tol­er­a­bil­i­ty pro­file com­pared with their fran­chise drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.